Latest Financials News

Articore Group reaffirms its FY25 financial guidance while initiating a strategic review to unlock shareholder value, coinciding with the appointment of Vivek Kumar as Group CEO.

GQG Partners has reported a steady rise in funds under management, reaching US$168.5 billion by the end of May 2025, supported by robust net inflows across key equity strategies.

Zip Co Limited has raised its FY25 cash EBTDA guidance to at least $160 million, driven by robust transaction growth in the US market exceeding 40% year-on-year in May 2025. The company also continues its share buy-back program amid steady credit performance.

Pilbara Minerals Limited has announced a significant 2025 Mineral Resource update for its Pilgangoora Operation, increasing contained lithium oxide by 23% to 5.7 million tonnes and reinforcing its status as a global lithium powerhouse.

Perseus Mining outlines a robust five-year gold production plan targeting up to 2.7 million ounces with stable costs and strong cash margins, backed by major projects in Africa.

Finbar Group has fast-tracked Ronald Chan’s appointment as CEO, aiming to leverage his deep company experience to strengthen its development pipeline and growth strategy.

Kore Potash Plc has had its trading suspension lifted following a key announcement about funding for its Kola Project, signaling renewed investor access and potential project momentum.

Kore Potash has signed non-binding term sheets with OWI-RAMS for a $2.2 billion funding package to develop its flagship Kola Potash Project in the Republic of Congo, combining senior secured finance and royalty-based funding under Shariah principles.

Patrys Limited has raised $358,362 through a share placement and announced significant board changes, including the appointment of Dr Anton Uvarov and Mr Peter Christie, alongside making the CEO role redundant.

VanEck Investments Limited has released a replacement Product Disclosure Statement for its VanEck Bentham Global Capital Securities Active ETF (ASX, GCAP), outlining an actively managed strategy focused on global subordinated debt securities with income and diversification benefits.

Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.

Macquarie Group Limited has updated its final dividend details, confirming a fully franked AUD 3.90 per share payout and setting the Dividend Reinvestment Plan price at AUD 213.66 based on recent trading averages.